Second trimester serum predictors of preterm birth in a population-based sample of low-risk pregnancies

Prenatal Diagnosis

Volumn 30, Issue 8, 2010, Pages 727-733

  Jelliffe Pawlowski, Laura L ^a   Baer, Rebecca J ^a   Currier, Robert J ^a  

^a CALIFORNIA DEPARTMENT OF PUBLIC HEALTH   (United States)

Author keywords

Biomarkers; Prenatal screening; Preterm birth; Second trimester; Unconjugated estriol

Indexed keywords

ALPHA FETOPROTEIN; BIOLOGICAL MARKER; CHORIONIC GONADOTROPIN; ESTRIOL; UNCLASSIFIED DRUG; UNCONJUGATED ESTRIOL;

ADULT; ANEUPLOIDY; ARTICLE; BIRTH WEIGHT; FEMALE; GESTATIONAL AGE; HUMAN; LIVE BIRTH; MAJOR CLINICAL STUDY; MATERNAL SERUM; NEURAL TUBE DEFECT; PREMATURE LABOR; PRIORITY JOURNAL; RISK FACTOR; SECOND TRIMESTER PREGNANCY;

ADOLESCENT; ADULT; ALPHA-FETOPROTEINS; BIOLOGICAL MARKERS; CHORIONIC GONADOTROPIN; ESTRIOL; FEMALE; HUMANS; INFANT, NEWBORN; LOGISTIC MODELS; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY TRIMESTER, SECOND; PREMATURE BIRTH; RISK FACTORS; YOUNG ADULT;

EID: 77955099371     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.2489     Document Type: Article

References (26)

1. Alexander GR, Himes JH, Kaufman RB, et al. 1996. A United States national reference for fetal growth. Obstet Gynecol 87(2): 163-168. (Pubitemid 26033124)
2. Behrman RE, Stith Butler A. 2007. Preterm Birth: Causes, Consequences, and Prevention. National Academies Press: Washington DC.
3. Chandra S, Scott H, Dodds L, et al. 2003. Unexplained elevated maternal serum alpha-fetoprotein and/or human chorionic gonadotropin and the risk of adverse outcomes. Am J Obstet Gyneco 189(3): 775-781.
4. Dugoff L, Hobbins JC, Malone FD, et al. 2005. Quad screen as a predictor of adverse pregnancy outcome. Obstet Gynecol 106(2): 260-267.
5. Duric K, Skrablin S, Lesin J, et al. 2003. Second trimester total human chorionic gonadotropin, alpha-fetoprotein and unconjugated estriol in predicting pregnancy complications other than fetal aneuploidy. Eur J Obstet Gynecol Reprod Biol 110(1): 12-15.
6. Edlow AG, Srinivas SK, Elovitz MA. 2007. Second-trimester loss and subsequent pregnancy outcomes: What is the real risk?. Am J Obstet Gynecol 197(6): 581-586.
7. Gagnon A, Wilson RD, Audibert F, et al. 2008. Obstetrical complications associated with abnormal maternal serum markers analytes. J Obstet Gynaecol Can 30(10): 918-949.
8. Goldenberg RL. 2002. The management of preterm labor. Obstet Gynecol 100(5): 1020-1037.
9. Heine RP, McGregor JA, Goodwin TM, et al. 2000. Serial salivary estriol to detect an increased risk of preterm birth. Obstet Gynecol 96(4): 490-497.
10. Kiran TS, Bethel J, Bhal PS. 2005. Correlation of abnormal second trimester maternal serum alpha-fetoprotein (MSAFP) levels and adverse pregnancy outcome. J Obstet Gynaecol 25(3): 253-256.
11. Kowalczyk TD, Cabaniss ML, Cusmano L. 1998. Association of low unconjugated estriol in the second trimester and adverse pregnancy outcome. Obstet Gynecol 91(3): 396-400.
12. Lachelin GC, McGarrigle HH. 1984. A comparison of saliva, plasma unconjugated and plasma total oestriol levels throughout normal pregnancy. Br J Obstet Gynaecol 91(12): 1203-1209.
13. Lepage N, Chitayat D, Kingdom J, Huang T. 2003. Association between second-trimester isolated high maternal serum maternal serum human chorionic gonadotropin levels and obstetric complications in singleton and twin pregnancies. Am J Obstet Gynecol 188(5): 1354-1359. (Pubitemid 36589135)
14. Martin JA, Hamilton BE, Sutton PD, et al. 2007. Births: final data for 2005. Natl Vital Stat Rep 56(6): 1-103.
15. Martin JA, Kung HC, Mathews TJ, et al. 2008. Annual summary of vital statistics: 2006. Pediatrics 121(4): 788-801.
16. McGregor JA, Hastings C, Dullien VV. 1998. A meta-analysis of salivary estriol (sE(3)) as a means to identify women at risk for preterm birth due to fetal-placental endocrine mechanisms. Prim Care Update Ob Gyns 5(4): 179.
17. McGregor JA, Jackson GM, Lachelin GC, et al. 1995. Salivary estriol as risk assessment for preterm labor: a prospective trial. Am J Obstet Gynecol 173(4): 1337-1342.
18. Moawad AH, Goldenberg RL, Mercer B, et al. 2002. The preterm prediction study. The value of serum alkaline phosphatase, alpha-fetoprotein, plasma corticotropin-releasing hormone, and other serum markers for the prediction of spontaneous preterm birth. Am J Obstet Gynecol 186(5): 990-996.
19. Rissanen A, Niemimaa M, Suonpaa M, et al. 2006. Pregnancy-associated plasma protein A, free human chorionic gonadotrophin and nuchal translucency as predictors of miscarriage. Clin Genet 69(3): 287-289.
20. Smith GC, Shah I, White IR, et al. 2006. Maternal and biochemical predictors of spontaneous preterm birth among nulliparous women: a systematic analysis in relation to the degree of prematurity. Int J Epidemiol 35(5): 1169-1177.
21. Tavor O, Shohat M, Lipitz S. 2007. The relationship between perinatal outcome of singleton pregnancies and isolated highly elevated levels of maternal serum human chorionic gonadotropin at mid-gestation. Is Med Assoc J 9(7): 509-512. (Pubitemid 47193377)
22. Vintzileos AM, Ananth CV, Smulian JC. 2002. The impact of prenatal care in the United States on preterm births in the presence and absence of antenatal high-risk conditions. Am J Obstet Gynecol 187(5): 1254-1257.
23. Vink J, Hickey K, Ghidini A, et al. 2009. Earlier gestational age at ultrasound evaluation predicts adverse neonatal outcomes in the preterm appropriate-for-gestational-age fetus with idiopathic oligohydramnios. Am J Perinatol 26(1): 21-25.
24. Vogel I, Thorsen P, Curry A, Sandager P, Uldbjerg N. 2005. Biomarkers for the prediction of preterm delivery. Acta Obstet Gynecol Scand 84(6): 516-525.
25. Yaron Y, Cherry M, Kramer RL, et al. 1999. Second-trimester maternal serum marker screening: maternal serum alphafetoprotein, beta-human chorionic gonadotropin, estriol, and their various combinations as predictors of pregnancy outcome. Am J Obstet Gynecol 181(4): 968-974.
26. Yaron Y, Ochshorn Y, Heifetz S, et al. 2002. First trimester maternal serum free human chorionic gonadotropin as a predictor of adverse pregnancy outcome. Fetal Diagn Ther 17(6): 352-356.